Admedus Ltd (ASX:AHZ) has successfully implanted an ADAPT® treated DurAVR™ 3D single-piece aortic valve in a second patient at the University Hospitals Leuven, Belgium, in its first-in-human surgical aortic valve replacement (SAVR) study.
The first patient was implanted in April and Admedus chief executive officer Wayne Paterson said both patients were recovering well.
He said: “The first patient, implanted with DurAVR™ 3D single-piece aortic valve on March 26, 2020, is doing well, over a month post-implantation and patient two is recovering as expected.
“Given the challenges that the COVID-19 pandemic is presenting for hospitals, it is encouraging to see the second surgery completed.
“We are grateful to the surgeon and the patient for undergoing the procedure.”
Fifteen patients are to be enrolled in the study and followed up for six months after implantation.
Unique tissue technology
In heart surgery, one of the biggest issues facing patients – and surgeons – is finding a replacement valve that will last the life of the patient.
The current commercial devices start failing as early as five years after the procedure.
Admedus’ ADAPT® tissue technology, invented by Perth professor Leon Neethling, has been taken from discovery to global commercialisation and has proven to be the only tissue to last beyond 10 years in the human body.
With 62 million people globally suffering from aortic stenosis – a condition that narrows the valve and in severe cases requires a repair or replacement procedure - this is a major market for Admedus.
Shares today have been up as much as 12 cents to $7.65 intra-day.